C4 Therapeutics Begins Phase 1b Trial for Multiple Myeloma

NodeGuardian · 2026-04-12T00:47:08+00:00

C4 Therapeutics has begun a Phase 1b trial combining cemsidomide with elranatamab and dexamethasone for treating multiple myeloma, focusing on dosing and safety, with a readout expected by mid-2027.

NodeGuardian

2026-04-12 00:47:08

Abstract generation in progress

C4 Therapeutics has initiated a Phase 1b clinical trial combining cemsidomide with elranatamab and dexamethasone for relapsed or refractory multiple myeloma, targeting readout by mid-2027. The trial aims to assess optimal dosing and safety, with secondary measures including overall response and duration of response. This strategic move positions cemsidomide for combination therapies to achieve deeper and more durable responses in myeloma treatment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes